Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia
Public ClinicalTrials.gov record NCT03238326. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia
Study identification
- NCT ID
- NCT03238326
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Enrollment
- 295 participants
Conditions and interventions
Conditions
Interventions
- Brexpiprazole Drug
Drug
Eligibility (public fields only)
- Age range
- 13 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 22, 2017
- Primary completion
- Apr 21, 2025
- Completion
- Apr 21, 2025
- Last update posted
- Feb 3, 2026
2017 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research Site #101 | Dothan | Alabama | 36303 | — |
| Clinical Research Site #128 | Anaheim | California | 92805 | — |
| Clinical Research Site #105 | Culver City | California | 90230 | — |
| Clinical Research Site #103 | Long Beach | California | 90807 | — |
| Clinical Research Site #136 | Atlanta | Georgia | 30331 | — |
| Clinical Research Site #148 | Kansas City | Kansas | 66160 | — |
| Clinical Research Site #138 | Lake Charles | Louisiana | 70629 | — |
| Clinical Research Site #124 | Las Vegas | Nevada | 89109 | — |
| Clinical Research Site #130 | New York | New York | 10036 | — |
| Clinical Research Site #100 | Rochester | New York | 14618 | — |
| Clinical Research Site #121 | Kinston | North Carolina | 28501 | — |
| Clinical Research Site #133 | Cincinnati | Ohio | 45219 | — |
| Clinical Research Site #113 | Garfield Heights | Ohio | 44125 | — |
| Clinical Research Site #102 | Oklahoma City | Oklahoma | 73116 | — |
| Clinical Research Site #135 | Tulsa | Oklahoma | 74136 | — |
| Clinical Research Site #140 | Frisco | Texas | 75034 | — |
| Clinical Research Site #108 | Everett | Washington | 98201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03238326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 3, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03238326 live on ClinicalTrials.gov.